Navigation Links
Sanford-Burnham and 60° Pharmaceuticals to pursue promising target for the treatment of dengue fever
Date:3/4/2013

LA JOLLA, Calif., March 4, 2013Sanford-Burnham Medical Research Institute (Sanford-Burnham) and 60 Pharmaceuticals, LLC, have entered into a partnership to test furin, a human proteinase, as a drug target for the treatment of dengue fever, one of the most common infectious diseases in the tropics and subtropics. 60 Pharmaceuticals, a philanthropic-for-profit company focused on neglected and rare diseases, agreed to provide funding to Sanford-Burnham for the first phase of research to explore inhibitors of furin.

Since viral genomes are too small to encode every protein needed for their survival, they take advantage of proteins in their human hosts. For the dengue virus and numerous other virusessuch as West Nile, Ebola, or yellow feverfurin is a vital host protein. For this reason, these viruses can only attack human cells that produce furin. Scientists at Sanford-Burnham are now trying to find a way to inhibit furin, making it impossible for the dengue virus to exploit and "hijack" a host cell.

"We're working on a new small-molecule furin inhibitor. It's a challenge to design, but could solve the toxicity problem that plagues existing viral inhibitors," explains Alex Strongin, Ph.D., professor in Sanford-Burnham's Infectious and Inflammatory Disease Center.

During the first phase of the research partnership, Drs. Alex Strongin and Maurizio Pellecchia and their laboratories at Sanford-Burnham will identify the most promising lead candidate from multiple small-molecule compounds they have already synthesized and tested in cell-based tests. They will evaluate each compound's absorption and distribution in the body (pharmacokinetics), as well as toxicity and efficacy in animal models. These data will inform potential second-phase research, which will focus on further developing the lead compound for oral application.

"The partnership with Sanford-Burnham exemplifies our commitment to developing treatments for the world's most challenging and neglected diseases, such as dengue fever," adds Geoffrey Dow, CEO of 60 Pharmaceuticals. "Only a combined effort can help address these challenges and make a real difference in the lives of millions of people living in regions affected by the dengue virus. Our goal is to find a treatment that is affordable, safe in warm and humid climates, and easy to administer."

Successfully designing a small-molecule inhibitor of furin that is safe and effective could have implications far beyond dengue fever. Given the protein's prevalence and important role in the lifecycle of a variety of viruses, a potent inhibitor could eventually lead to treatment options for many more viral diseases, affecting hundreds of millions of people worldwide.


'/>"/>

Contact: Deborah Robison
drobison@sanfordburnham.org
407-745-2073
Sanford-Burnham Medical Research Institute
Source:Eurekalert

Related biology news :

1. Californias stem cell agency boosts heart disease research at Sanford-Burnham
2. NIH New Innovator Award helps Sanford-Burnham scientist pursue high-risk, high-reward project
3. Sanford-Burnham and Intrexon Corporation establish collaboration to accelerate stem cell research
4. From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals
5. Tokai Pharmaceuticals galeterone well-tolerated in patients with advanced prostate cancer
6. Fish show autism-like gene expression in water with psychoactive pharmaceuticals
7. AcelRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral Transmucosal Dosage Forms
8. Conatus Pharmaceuticals Appoints Mark F. Morris as Head of Biostatistics
9. Combination of two pharmaceuticals proves effective in the treatment of multiple sclerosis
10. Researchers pursue red flag for schizophrenia relapse
11. University of Arizona Engineering College pursues water technology innovation cluster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... , July 20, 2017 Delta (NYSE: DAL ... board any Delta aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics to ... Delta,s biometric ... Sky Club is now integrated into the boarding process to allow ...
(Date:5/23/2017)... robotic gym for the rehabilitation and functional motor sense evaluation of lower ... . The first 30 robots will be available from June in ... The technology was developed and patented at the IIT laboratories and has ... to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:4/24/2017)... -- Janice Kephart , former 9/11 Commission ... LLP (IdSP) , today issues the following statement: ... 6, 2017 Executive Order: Protecting the Nation ... instilled with greater confidence, enabling the reactivation of ... are suspended by until at least July 2017). ...
Breaking Biology News(10 mins):
(Date:8/16/2017)... and OXFORD, England , Aug. 16, ... consortium for biotech executive search and leadership development, and Virdis ... sectors, have created an exclusive alliance that enables clients to ... "For our clients here in the ... unparalleled access to a diverse population of leadership talent throughout ...
(Date:8/15/2017)... Boston, MA (PRWEB) , ... August 15, 2017 , ... ... unmet need that has compromised these disciplines for more than half a century. ... cannot be counted. It is widely known that molecular tags developed for this ...
(Date:8/14/2017)... (PRWEB) , ... August 14, 2017 , ... ... characterized and performing antibodies. Key researchers in the antibody community have recently come ... and consistency for antibodies in the laboratory. , The team at ...
(Date:8/11/2017)... ... ... Algenist continues to disrupt the skincare industry with today’s debut of GENIUS ... is the key structural element skin needs to maintain its youthful appearance and Algenist ... First to market with proprietary collagen water active , ...
Breaking Biology Technology: